Full-Time

DevOps Engineer

Updated on 8/1/2026

Deadline 6/12/27
Bruker Corporation

Bruker Corporation

1,001-5,000 employees

Develops analytical instruments for scientific research

No salary listed

Bremen, Germany

Hybrid

Flexible work from home or the office is available.

Category
DevOps & Infrastructure (1)
Required Skills
Kubernetes
Microsoft Azure
Python
Software Testing
Git
Docker
Maven
Terraform
Ansible
DevOps

Get referred to Bruker Corporation

See people who can refer or advise you

Requirements
  • A degree in computer science or equivalent knowledge and practical experience.
  • Around two years of professional experience in DevOps, combined with hands-on software development experience and a strong understanding of software development practices.
  • Strong hands-on experience with Terraform, Ansible, Docker and Docker Compose, Python, and CI/CD platforms such as GitHub.
  • Very good German and good English language skills.
Responsibilities
  • Design, implement, and operate automated infrastructure and deployment pipelines supporting the software products in microbial identification.
  • Support the full lifecycle of systems, from infrastructure provisioning and configuration to deployment, monitoring, and continuous improvement.
  • Establish and maintain CI/CD pipelines to ensure reliable, reproducible, and high-quality software deliveries.
  • Work closely with software developers, architects, and other stakeholders in an interdisciplinary and globally distributed team.
  • Actively contribute ideas and hands-on expertise to improve system stability, scalability, and operational excellence.
Desired Qualifications
  • Knowledge of test automation, Maven, .NET Core, and Kubernetes is considered a plus.
  • At least two years of experience with a major cloud infrastructure provider, preferably Microsoft Azure.

Bruker Corporation provides analytical and diagnostic instruments used in life sciences, materials science, and environmental analysis. Its product lines include technologies such as nuclear magnetic resonance (NMR), mass spectrometry, imaging, and spectroscopy, which help researchers analyze the composition, structure, and properties of samples. These instruments work by measuring physical signals (like magnetic resonance, ion fragmentation patterns, or spectral fingerprints) from samples and translating them into data and insights via specialized software and workflows. Bruker differentiates itself through a long history of NMR expertise since 1960, a broad, integrated portfolio of measurement platforms, and a global footprint that supports researchers from development to routine analysis. Its goal is to empower scientists and industry professionals to advance research and solve real-world problems by providing reliable analytical tools and solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Billerica, Massachusetts

Founded

1960

Get referred to Bruker Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • DISQVER targets sepsis, endocarditis, and bloodstream infections with under-24-hour analysis.[1]
  • Bruker can cross-sell NGS, AST, hygiene, and molecular diagnostics into hospitals.[1]
  • Select acquisition of distressed IP and staff can expand capabilities efficiently.[1]

What critics are saying

  • DISQVER remains research use only, delaying diagnostic revenue until registration completes.[1]
  • Noscendo's insolvency exposed weak commercialization and hospital budget pressure.[1]
  • Bruker faces integration risk from acquired software, IP, and select personnel.[1]

What makes Bruker Corporation unique

  • Founded by Günther Laukien in 1960, rooted in NMR innovation.[1][5]
  • Broad portfolio spans analytical instruments, diagnostics, microscopy, and semiconductor metrology.[1]
  • DISQVER adds metagenomic blood testing to Bruker's infection-diagnostics platform.[1]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Life Insurance

Dental Insurance

Flexible Work Hours

Employee Discounts

Growth & Insights and Company News

Headcount

6 month growth

14%

1 year growth

14%

2 year growth

14%
brutkasten GmbH
Jul 23rd, 2026
Bruker acquires DISQVER platform from insolvent German diagnostics startup Noscendo

US life sciences company Bruker has acquired the DISQVER platform and selected assets of insolvent German diagnostics startup Noscendo through a restructuring sale. Financial terms were not disclosed. Duisburg-based Noscendo, founded in 2016, developed a method for identifying pathogens in under 24 hours using next-generation sequencing from cell-free DNA. The technology is used by university hospitals for sepsis diagnostics. Despite raising nearly €40 million in venture capital, commercialisation proceeded slower than expected due to delays in selective contracts and economic pressure on hospitals. A planned financing round with existing investors failed in February 2026, leading to insolvency proceedings in March. Insolvency administrator Sarah Wolf from Anchor Rechtsanwälte said the restructuring preserved the technology's value for creditors and partners. Bruker acquired the patent-protected software, intellectual property rights, and select IT and sales staff in Duisburg. The laboratory in Kusterdingen was partially closed in April.